SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): December 1,
2009
Urigen
Pharmaceuticals, Inc.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
0-22987
|
94-3156660
|
||
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
27 Maiden Lane, San Francisco,
California
|
94108
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (650) 259-0239
(Former
name or former address, if changed since last report)
Copies
to:
Marc
Ross, Esq.
Thomas
Rose, Esq.
Sichenzia
Ross Friedman Ference LLP
61
Broadway, 32nd
Floor
New York,
New York 10018
Phone:
(212) 930-9700
Fax:
(212) 930-9725
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instructions A.2. below):
/_/
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
/_/
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
/_/
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
/_/
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item
5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On
December 3, 2009, the Board of Directors of Urigen Pharmaceuticals, Inc. (the
“Company”) appointed Edward R. Teitel to serve as a Director of the
Company.
Edward R. Teitel, M.D., J.D. M.B.A. –
Director
Dr.
Teitel, age 61, currently serves as the President and Chief Executive Officer of
ThromboVision, Inc. Prior to founding ThromboVision in 2005, Dr. Teitel served
as Senior Vice President and Chief Medical Officer at MicroMed Technology, Inc.
(now MicroMed Cardiovascular, Inc.). As a part of senior management at MicroMed,
Dr. Teitel participated in all aspects of clinical trials and regulatory
matters, business scope and fund raising activities, as well as legal matters.
As chief medical officer for the DeBakey Left Ventricular Assist Device at
MicroMed, Dr. Teitel acquired extensive experience in platelet function and
anti-platelet therapy, especially relating to artificial surface
devices.
Before
joining MicroMed Technology in 2002, Dr. Teitel practiced for many years as a
board certified general and vascular surgeon. He founded, managed, and developed
a multi-specialty group practice in Alabama until he closed his practice in 1997
to transition into corporate medicine and management.
Dr.
Teitel earned his MBA at Auburn University and worked with a boutique investment
banking firm, Colby Capital, in Atlanta where he worked to fund start-up
companies in the life sciences. After completing law school in 2002, he joined
the senior management team at MicroMed.
Dr.
Teitel earned his MD degree at the University of Texas Health Science Center at
San Antonio, and completed his surgical residency at St. Mercy Medical Hospital
in Pontiac, Michigan. He received his Juris Doctor degree from the University of
Houston, with a focus in healthcare law, intellectual property and business law.
Dr. Teitel holds a BS in chemistry from Sul Ross State University.
Also, on
December 1, 2009, Cynthia Sullivan and George Lasezkay tendered their
resignations as Directors of the Company.
SIGNATURE
Pursuant to the requirements of
Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the Undersigned, thereunto
duly authorized.
Urigen Pharmaceuticals, Inc. | |||
Date: December
7, 2009
|
By:
|
/s/ William J. Garner | |
William J.
Garner, M.D.
Chief
Executive Officer
|
|||